Eydisbio Inc. has been awarded a $2.6 million phase II Small Business Innovation Research (SBIR) grant from the National Institute of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI) to support its ongoing research into the efficacy of TAK1 inhibition in animal models of systemic sclerosis.

Since the publication of The Hallmarks of Aging in 2013, aging research has exploded. The field now has more than 300,000 articles on the biological signals of the effect of time on the body. What would Marty McFly, the legendary character from the Back to the Future saga who traveled with his DeLorean time machine from the ‘80s to the ‘50s, think if he visited 2024 and saw laboratories experimenting with techniques to turn back the biological clocks of cells or increase the lifespan of rejuvenated mice?

Researchers from Thomas Jefferson University and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) have published findings from preclinical studies of LASSARAB, a new rabies-based Lassa virus (LASV) vaccine candidate.

Immorna Biotherapeutics Inc. has received a grant from the Bill & Melinda Gates Foundation to support the clinical development of JCXH-108, a monovalent respiratory syncytial virus (RSV) vaccine based on Immorna’s proprietary mRNA and ready-to-use (RTU)-lipid nanoparticle (LNP) technologies.

The efficacy of seasonal flu vaccines varies due to the ability of the influenza virus to mutate rapidly. The achievement of a universal flu vaccine conferring protection against all strains, including those with pandemic potential, for longer than a single season would provide a great benefit and has not yet been achieved.

Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne have discovered new cells that drive the aging process in the thymus that could unlock a way to restore function and prevent immunity from waning as we age. The thymus is the first organ in the body to shrink as people age. As this happens, the T-cell growth areas in the thymus are replaced with fatty tissue, diminishing T-cell production and contributing to a weakened immune system.

G protein-coupled receptor kinase 2 (GRK2) is a crucial kinase that has been shown to interact with multiple signaling molecules under different pathological conditions, including fibrosis.

The risk of developing multiple sclerosis (MS) is nearly four times as high for women as it is for men. And that relative risk has increased sharply over time. In 1955, women were only slightly more likely than men to develop MS. A research team at the University of Toronto and the Oklahoma Medical Research Foundation (OMRF) has gained new insights into possible causes for this increasing disparity.

Tonix Pharmaceuticals Holding Corp. is advancing development of its live attenuated virus vaccine, TNX-801 (recombinant horsepox virus), for preventing mpox and other infectious diseases.

Immunesensor Therapeutics Inc. has received Human Research Ethics Committee (HREC) approval and clinical trial notification (CTN) clearance by Australia’s Therapeutic Goods Administration (TGA) to initiate a phase I study of IMSB-301, a novel, orally available small-molecule cGAS inhibitor that is being developed for the treatment of inflammatory and autoimmune diseases.